Actively Recruiting
A Study of BGM-2121 in Patients With Advanced Solid Tumors
Led by BioGate Precision Medicine Corp. · Updated on 2026-04-21
35
Participants Needed
3
Research Sites
142 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
CONDITIONS
Official Title
A Study of BGM-2121 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Confirmed diagnosis of advanced solid tumors
- Previously received and failed standard anti-cancer therapy
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
You will not qualify if you...
- Ongoing toxicity from previous anti-cancer treatments
- Signs or symptoms of end-stage organ failure or major chronic illnesses other than cancer
- History of another primary malignancy within the last three years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
National Cheng Kung University Hospital
Tainan, Taiwan
Not Yet Recruiting
2
National Taiwan University Hospital
Taipei, Taiwan
Not Yet Recruiting
3
Taipei Veterans General Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
Q
Queena Hwang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here